02:00 Tue 01 Dec 2020
Futura Medical PLC - Block Listing Six Monthly Return
Block Listing Six Monthly Return
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of
Date:
Name of applicant: |
Futura Medical Plc |
|||
Name of scheme: |
Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme |
|||
Period of return: |
From: |
|
To: |
|
Balance of unallotted securities under scheme(s) from previous return: |
9,306,779 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
n/a |
|||
Less: Number of securities issued/allotted under scheme(s) during period: |
n/a |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
9,306,779 |
|||
Number and class of securities originally admitted and the date of admission |
USOS Total: 3,882,912 814,424 1,202,280 1,466,208 400,000
USIS Total: 425,000 425,000
EMI Total: 7,012,088 1,520,576 1,467,720 1,893,792 790,000 1,340,000 |
|||
For further information please contact:
Futura Medical plc
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.
Futura is based in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE